Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D02DTQ
|
|||
| Former ID |
DIB016648
|
|||
| Drug Name |
PF-3893787
|
|||
| Synonyms |
PF-03893787; PF-3826719
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Atopic dermatitis [ICD-11: EA80; ICD-10: L20; ICD-9: 691.8, 692.9] | Phase 2 | [1] | |
| Plaque psoriasis [ICD-11: EA90.0; ICD-10: L40.0] | Phase 2 | [2] | ||
| Asthma [ICD-11: CA23; ICD-10: J45, J45.8; ICD-9: 493] | Phase 1 | [3] | ||
| Company |
Pfizer Inc
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C13H22N6
|
|||
| Canonical SMILES |
CNC1CCN(C1)C2=NC(=NC(=C2)NCC3CC3)N
|
|||
| InChI |
1S/C13H22N6/c1-15-10-4-5-19(8-10)12-6-11(17-13(14)18-12)16-7-9-2-3-9/h6,9-10,15H,2-5,7-8H2,1H3,(H3,14,16,17,18)/t10-/m1/s1
|
|||
| InChIKey |
ISBHYKVAFKTATD-SNVBAGLBSA-N
|
|||
| CAS Number |
CAS 943057-12-3
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Histamine H4 receptor (H4R) | Target Info | Antagonist | [3] |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Reactome | Histamine receptors | |||
| G alpha (i) signalling events | ||||
| WikiPathways | GPCR ligand binding | |||
| GPCR downstream signaling | ||||
| GPCRs, Other | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Challenges of drug discovery in novel target space. The discovery and evaluation of PF-3893787: a novel histamine H4 receptor antagonist. Bioorg Med Chem Lett. 2011 Nov 1;21(21):6596-602. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.